Symrise presents clinical evidence for skin and digestive health at SupplySide Global 2026
- Acerowell: 600 mg/day for 12 weeks in 108 women (45–60) significantly improved skin radiance and translucency, with >80% reporting better luminosity, complexion and texture.
- Rham271h postbiotic is derived from Lacticaseibacillus rhamnosus 6594; it is heat- and pH-resistant, shows in vitro increases in anti-inflammatory IL-10 and supports gut barrier integrity, and is dosed at 10 billion TFU/day.
- LP299V® + LPGOS42™ dual-strain eight‑week RCT in 100 adults with occasional constipation significantly improved digestive comfort, regularity and quality-of-life versus placebo; a subgroup with ≤3 weekly BMs had larger increases in complete spontaneous bowel movements.
- Symrise will showcase these ingredients, formulation concepts and application expertise at Booth 2364 at SupplySide Global 2026, marking the first joint Americas presence of Probi and Health Active Solutions.
Event presence
Symrise’s Care & Wellness Division will jointly present Health Active Solutions and Probi in the Americas at SupplySide Global 2026, booth 2364, showcasing clinical evidence, biotic technologies and formulation concepts for human and pet health.
Acerowell clinical data
In a randomized, placebo‑controlled study of 108 women aged 45–60, daily supplementation with 600 mg Acerowell for 12 weeks significantly improved skin radiance and translucency versus placebo; more than 80% of participants reported improvements in luminosity, complexion and texture. Symrise standardizes and vertically integrates the acerola powder and positions Acerowell for powders, gummies and functional beverages with visible results from the first month.
Rham271h postbiotic
Rham271h is an inactivated postbiotic derived from Lacticaseibacillus rhamnosus 6594; its pH and heat resistance support stable, versatile applications beyond live probiotics. In‑vitro data indicate modulation of immune‑related biomarkers, including increased IL‑10, and support for gut barrier integrity, with a recommended daily dose of 10 billion TFU for supplements and functional foods/beverages.
Probiotic clinical evidence
An eight‑week randomized, placebo‑controlled study of 100 adults with occasional constipation showed the LP299V® + LPGOS42™ combination significantly improved digestive comfort, regularity and quality‑of‑life versus placebo. A post‑hoc analysis of participants reporting three or fewer weekly bowel movements (about 80% of the cohort) showed a significantly greater increase in weekly complete spontaneous bowel movements.
Applications and strategy
Symrise will present market‑ready formulation concepts, recipes and taste‑balancing solutions in beverages, stick packs and chewables, illustrating how clinically supported ingredients and complementary biotic technologies can be translated into targeted products for Women’s Health, Longevity, Digestive Health and Sports & Active Nutrition.
Source: Symrise